In Bid to Expand Genetic Testing Business, PerkinElmer Launches $300M Bid for ViaCell | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Just a few days after PerkinElmer officials said that the firm’s acquisition priorities begin with expanding its genetic testing business, the firm this week agreed to buy ViaCell, a Cambridge, Mass.-based specialty stem cell company, for around $300 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.